Literature DB >> 7140803

Metabolic oxidation of methaqualone in extensive and poor metabolisers of debrisoquine.

M Oram, K Wilson, D Burnett, S G Al-Dabbagh, J R Idle, R L Smith.   

Abstract

The metabolism of methaqualone to the glucuronides of 5 C-monohydroxy metabolites and to the N-oxide has been studied in 2 groups of healthy young adults phenotyped as extensive and poor metabolisers of debrisoquine. No significant interphenotype differences were observed with respect to the excretion of any of the 6 metabolites. It is probable that the genetic regulation of the pathways leading to these metabolites is at a locus other than that which is responsible for the regulation of the oxidation of debrisoquine, guanoxan, phenacetin, phenytoin and sparteine.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7140803     DOI: 10.1007/bf00545969

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  15 in total

1.  Polymorphism of carbon oxidation of drugs and clinical implications.

Authors:  T P Sloan; A Mahgoub; R Lancaster; J R Idle; R L Smith
Journal:  Br Med J       Date:  1978-09-02

2.  Genetic evidence for the involvement of different oxidative mechanisms in drug oxidation.

Authors:  L A Wakile; T P Sloan; J R Idle; R L Smith
Journal:  J Pharm Pharmacol       Date:  1979-05       Impact factor: 3.765

3.  Bioavailability of methaqualone.

Authors:  R D Smyth; J K Lee; A Polk; P B Chemburkar; A M Savacool
Journal:  J Clin Pharmacol       Date:  1973-10       Impact factor: 3.126

4.  A family and population study of the genetic polymorphism of debrisoquine oxidation in a white British population.

Authors:  D A Evans; A Mahgoub; T P Sloan; J R Idle; R L Smith
Journal:  J Med Genet       Date:  1980-04       Impact factor: 6.318

5.  Methaqualone metabolism by rat liver microsomes.

Authors:  P Manowitz; C M Shull
Journal:  Res Commun Chem Pathol Pharmacol       Date:  1976-01

6.  The effect of age on the hydroxylation of amylobarbitone sodium in man.

Authors:  R E Irvine; J Grove; P A Toseland; J R Trounce
Journal:  Br J Clin Pharmacol       Date:  1974-02       Impact factor: 4.335

7.  Defective N-oxidation of sparteine in man: a new pharmacogenetic defect.

Authors:  M Eichelbaum; N Spannbrucker; B Steincke; H J Dengler
Journal:  Eur J Clin Pharmacol       Date:  1979-09       Impact factor: 2.953

8.  Urinary excretion of methaqualone-N-oxide in man.

Authors:  C N Reynolds; K Wilson; D Burnett
Journal:  Xenobiotica       Date:  1976-02       Impact factor: 1.908

9.  Deficient metabolism of debrisoquine and sparteine.

Authors:  T Inaba; S V Otton; W Kalow
Journal:  Clin Pharmacol Ther       Date:  1980-04       Impact factor: 6.875

10.  Polymorphic hydroxylation of Debrisoquine in man.

Authors:  A Mahgoub; J R Idle; L G Dring; R Lancaster; R L Smith
Journal:  Lancet       Date:  1977-09-17       Impact factor: 79.321

View more
  4 in total

1.  Clinical significance of the sparteine/debrisoquine oxidation polymorphism.

Authors:  K Brøsen; L F Gram
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953

2.  Identification and molecular characterization of miRNAs and their target genes associated with seed development through small RNA sequencing in chickpea.

Authors:  Subodh Verma; Anirban Chakraborty; Seema Pradhan; Sabhyata Bhatia
Journal:  Funct Integr Genomics       Date:  2021-02-25       Impact factor: 3.410

Review 3.  Physiological changes during the menstrual cycle and their effects on the pharmacokinetics and pharmacodynamics of drugs.

Authors:  A D Kashuba; A N Nafziger
Journal:  Clin Pharmacokinet       Date:  1998-03       Impact factor: 6.447

4.  The effect of age on the competitive C- and N-oxidative pathways of methaqualone in women.

Authors:  K Wilson; M Oram; D Burnett
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1984 Oct-Dec       Impact factor: 2.441

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.